IRIS
MOIA, RICCARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.367
NA - Nord America 2.043
AS - Asia 1.672
SA - Sud America 208
AF - Africa 87
OC - Oceania 4
Totale 6.381
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.939
RU - Federazione Russa 752
SG - Singapore 557
IT - Italia 553
IE - Irlanda 293
CN - Cina 283
HK - Hong Kong 246
DE - Germania 212
VN - Vietnam 199
BR - Brasile 174
BD - Bangladesh 144
SE - Svezia 141
FR - Francia 127
IN - India 85
GB - Regno Unito 81
CA - Canada 62
UA - Ucraina 47
FI - Finlandia 41
BJ - Benin 40
KR - Corea 39
MX - Messico 33
PL - Polonia 27
ID - Indonesia 20
JP - Giappone 20
TR - Turchia 20
ZA - Sudafrica 17
AT - Austria 14
LT - Lituania 14
ES - Italia 13
NL - Olanda 13
IQ - Iraq 12
AR - Argentina 11
CZ - Repubblica Ceca 8
EC - Ecuador 8
ET - Etiopia 8
SA - Arabia Saudita 8
IR - Iran 6
BE - Belgio 5
CO - Colombia 5
EG - Egitto 5
PH - Filippine 5
AU - Australia 4
KE - Kenya 4
MD - Moldavia 4
PE - Perù 4
PK - Pakistan 4
UZ - Uzbekistan 4
AL - Albania 3
CR - Costa Rica 3
DK - Danimarca 3
HR - Croazia 3
NG - Nigeria 3
SY - Repubblica araba siriana 3
VE - Venezuela 3
AO - Angola 2
CH - Svizzera 2
CL - Cile 2
DZ - Algeria 2
GR - Grecia 2
IL - Israele 2
JM - Giamaica 2
KG - Kirghizistan 2
MA - Marocco 2
MY - Malesia 2
OM - Oman 2
RS - Serbia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MK - Macedonia 1
NP - Nepal 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
SN - Senegal 1
SV - El Salvador 1
TN - Tunisia 1
Totale 6.381
Salva come PNG Salva come JPEG
Città #
San Jose 343
Dublin 291
Hong Kong 244
Singapore 226
Ashburn 185
Beijing 109
Council Bluffs 100
Los Angeles 95
Jacksonville 70
Lauterbourg 70
Chandler 66
Moscow 65
Novara 65
New York 59
Ho Chi Minh City 56
Boardman 49
Hanoi 49
Munich 47
Milan 42
Cotonou 40
Piemonte 38
Buffalo 37
Seoul 34
Helsinki 33
Lawrence 33
Princeton 33
St Louis 33
Vercelli 32
Santa Clara 31
Columbus 28
Frankfurt am Main 27
Orem 27
Bremen 25
São Paulo 25
Turin 25
Toronto 24
Warsaw 23
Falkenstein 22
Dallas 21
Mexico City 21
Chennai 19
Grafing 19
Wilmington 19
Tornaco 18
London 17
Tokyo 17
Atlanta 16
Brooklyn 16
Houston 15
Nuremberg 15
Poplar 15
Denver 14
Montreal 14
Rome 14
Johannesburg 13
Podenzano 13
San Mateo 13
Hillsboro 12
Boston 11
Chicago 11
Belo Horizonte 10
Mumbai 10
Phoenix 10
Ankara 9
Cassano Magnago 9
Redondo Beach 9
Addis Ababa 8
Genoa 8
Haiphong 8
Manchester 8
Roseto degli Abruzzi 8
Stockholm 8
Amsterdam 7
Augusta 7
Bologna 7
City of London 7
Da Nang 7
Gallarate 7
Ottawa 7
Turku 7
Ann Arbor 6
Bexley 6
Brno 6
Guangzhou 6
Hangzhou 6
Menlo Park 6
Naples 6
Rimini 6
Roubaix 6
Shanghai 6
Strasbourg 6
West Jordan 6
Barnet 5
Berlin 5
Brussels 5
Charlotte 5
Dalian 5
Gunzenhausen 5
Jakarta 5
New Delhi 5
Totale 3.417
Salva come PNG Salva come JPEG
Nome #
Molecular clustering on ctDNA improves the prognostic stratification of DLBCL patients compared to ctDNA levels 175
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia 150
Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome 141
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement 138
Active AKT signaling triggers CLL towards Richter's transformation via over-activation of Notch1 136
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia 133
Targeting p53 in chronic lymphocytic leukemia 132
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 123
A leukemia-protective germline variant mediates chromatin module formation via transcription factor nucleation 120
Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma 119
An update on: molecular genetics of high-risk chronic lymphocytic leukemia 115
Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity 115
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment 111
Precision medicine management of chronic lymphocytic leukemia 110
Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms 110
Druggable Molecular Pathways in Chronic Lymphocytic Leukemia 109
Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients 107
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 106
CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression 102
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations 102
High Mitophagy and Low Glycolysis Predict Better Clinical Outcomes in Acute Myeloid Leukemias 100
An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient 100
Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome 99
High reproducibility of spleen stiffness measurement by vibration-controlled transient elastography with a spleen-dedicated module 96
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 96
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 96
Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination 94
High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy 92
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL 91
XPO1 mutations identify early‐stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 91
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 91
A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab 90
The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications 90
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 89
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 87
Prognostic value of clonal evolution identified by sequential FISH in untreated chronic lymphocytic leukaemia 86
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 86
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 86
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib 84
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial 84
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 83
Cerebrospinal fluid xanthochromia after pegasparaginase hepatotoxicity in B-cell acute lymphoblastic leukemia 83
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 81
Liquid biopsy in hematological malignancies: current and future applications 79
Inducible T-cell co-stimulator (ICOS) and ICOS ligand are novel players in the multiple-myeloma microenvironment 78
Prognostication in chronic lymphocytic leukemia 77
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study 76
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma 74
Prevalence and clinical impact of clonal hematopoiesis of indeterminate potential (CHIP) in chronic lymphocytic leukemia and richter transformation 74
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia 73
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 72
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia 70
Reply to Aron P. Kater et al 70
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation 69
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 68
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 64
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 63
CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience 62
HL-370 Fragmentóme Profiling Reveals Distinct Molecular Subgroups of Classic Hodgkin Lymphoma 62
null 62
Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma 55
Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia 55
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy 52
Unraveling the Epigenetic Landscape of Mature B Cell Neoplasia: Mechanisms, Biomarkers, and Therapeutic Opportunities 51
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside 51
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands 49
A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA 48
Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV ‐Positive Patient: A Case Report 44
Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy 43
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL 40
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 39
Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation 32
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trial 32
Diagnostic Challenges in a Young Man with a Suspected Mast Cell Disorder, Dysplastic Bone Marrow Morphology, and a ZRSR2 Mutation 30
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms 26
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker 23
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes 17
Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology 17
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R) 15
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study 13
Secondary Genetic Events and Their Relationship to TP53 Mutation in Mantle Cell Lymphoma: A Sub-Study from the FIL_MANTLE-FIRST BIO on Behalf of Fondazione Italiana Linfomi (FIL) 8
Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma 8
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study 8
Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study 7
Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring 6
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL 5
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 5
Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics 4
Molecular Pathogenesis and Targeted Treatment of Richter Transformation 4
Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice 4
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12 3
Clonal hematopoiesis dynamics influences long‐term outcomes of follicular lymphoma: Results from FIL FOLL12 trial 3
Clinical Outcomes in Double-Exposed Chronic Lymphocytic Leukemia Patients in Italy 2
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 2
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study 2
Totale 6.525
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.746
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.746
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022243 2 5 10 11 21 3 24 3 6 25 63 70
2022/2023633 43 33 51 10 39 44 32 30 277 6 51 17
2023/2024359 28 29 33 12 44 11 46 4 1 17 38 96
2024/2025997 16 12 70 14 37 51 89 224 188 85 37 174
2025/20264.037 176 126 217 442 425 277 563 606 305 336 372 192
Totale 6.525